• 1
    Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 2004; 4: 72538.
  • 2
    Eizuru Y, Minematsu T, Minamishima Y et al. Rapid diagnosis of cytomegalovirus infection by direct immunoperoxidase staining with human monoclonal antibody against an immediate early antigen. Microbiol. Immunol. 1991; 35: 101522.
  • 3
    Murry BM, Amsterdam D, Gray V et al. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation. J. Am. Soc. Nephrol. 1997; 8: 144857.
  • 4
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med. 1998; 338: 174151.
  • 5
    Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leucocytes after allogeneic marrow transplantation. Blood 1992; 80: 135864.
  • 6
    Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 406371.
  • 7
    Kanda Y, Mineishi S, Saito T et al. Preemptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant. 2001; 27: 43744.
  • 8
    Pellegrin I, Garrgue I, Binquet C et al. Evaluation of new quantitative assay for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J. Clin. Microbiol. 1999; 37: 312432.
  • 9
    American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277304.
  • 10
    Ljungman P, Griffths P, Paya C. Definition of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis. 2002; 34: 10947.
  • 11
    Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical application. Clin. Microbiol. Rev. 1998; 11: 53354.
  • 12
    Yamashita M, Ishii T, Iwama N et al. Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose corticosteroid therapy for collagen vascular diseases. Clin. Exp. Rheumatol. 2006; 24: 64955.
  • 13
    Yoda Y, Hanaoka R, Ide H et al. Clinical evaluation of patients with inflammatory connective tissue disease complicated by cytomegalovirus antigenemia. Mod. Rheumatol. 2006; 16: 13742.
  • 14
    Takizawa Y, Inokuma S, Tanaka Y et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 2008; 47: 13738.
  • 15
    Matsuoka K, Iwao Y, Mori T et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am. J. Gastroenterol. 2007; 102: 3317.
    Direct Link:
  • 16
    Einsele H, Ehninger G, Steidle M et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 16728.
  • 17
    Winston DJ, Ho WG, Lin CH et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 1987; 106: 128.
  • 18
    Ljungman P, Cordonnier C, Einsele H et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1998; 21: 4736.
  • 19
    Raanani P, Gafter-Gvili A, Paul M et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systemic review and meta analysis. J. Clin. Oncol. 2009; 27: 77081.
  • 20
    Papazian L, Fraisse A, Garbe L et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996; 84: 2807.
  • 21
    Kutza AS, Muhl E, Hackstein H et al. High incidence of active cytomegalovirus infection among septic patients. Clin. Infect. Dis. 1998; 26: 107682.
  • 22
    Mutimer D, Milza D, Shaw J et al. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 1997; 63: 141115.
  • 23
    Jaber S, Chanques G, Borry J et al. Cytomegalovirus infection in critically ill patients. Associated factors and consequences. Chest 2005; 127: 23341.
  • 24
    Limaye AP, Kirby KA, Rubenfeld KA et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300: 41322.
  • 25
    Döcke W, Prösch S, Fietze E. Cytomegalovirus reactivation and tumor necrosis factor. Lancet 1994; 343: 2689.
  • 26
    Cook CH, Trgovcich J, Zimmerman PD et al. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1β triggers reactivation of latent cytomegalovirus in immunocompetent mice. J. Virol. 2006; 80: 91518.
  • 27
    Pan LH, Ohtani H, Yamauchi K et al. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol. Int. 1996; 46: 919.
  • 28
    Boeckh M, Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 571119.